-
Amgen Launches Global Collaboration Network to Advance Oncology Research
•
Amgen (NASDAQ: AMGN) has announced the launch of a new collaboration network that connects its oncology team with eight prominent research centers across Australia, Canada, France, Germany, South Korea, Spain, and the United States. This initiative is designed to accelerate the development of new cancer treatments for conditions with unmet…
-
Roche’s Genentech Partners with Orionis Biosciences for Molecular Glue Therapies
•
Genentech, a subsidiary of Swiss pharmaceutical giant Roche (SWX: ROG), has announced a partnership with Belgium-based Orionis Biosciences to discover molecular glue-class small-molecule treatments in oncology and neurodegeneration. This strategic collaboration aims to leverage Orionis’s proprietary platform for high-throughput discovery, rational design, and optimization of candidates that modulate intermolecular interactions,…
-
Suzhou Zelgen Biopharmaceuticals’ ZG005 Receives NMPA Approval for Solid Tumor Trial
•
Suzhou Zelgen Biopharmaceuticals Co., Ltd (SHA: 688266), a China-based pharmaceutical company, has announced that it has received clinical trial approval from the National Medical Products Administration (NMPA) for its pipeline drug candidate, ZG005. The trial will evaluate the efficacy of ZG005 in combination with the Category 1 anti-cancer drug donafenib…
-
Antengene’s Anti-CD24 Antibody ATG-031 Gets Green Light for Phase I Study at MD Anderson
•
Antengene Corporation Ltd (HKG: 6996), a China-based biopharmaceutical company, has announced that the Institutional Review Board (IRB) of The University of Texas MD Anderson Cancer Center in Houston, Texas, has approved a Phase I study for its best-in-class anti-CD24 antibody, ATG-031. The clinical study, codenamed the PERFORM trial and led…
-
Inmagene Biopharmaceuticals and Aditum Bio Launch JV Celexor Bio to Target Autoimmune Diseases
•
Inmagene Biopharmaceuticals, a China-based biopharmaceutical company, has announced a strategic collaboration with US firm Aditum Bio to establish Celexor Bio, a joint venture (JV) focused on utilizing the mechanism of clearing pathological cells to treat autoimmune and inflammatory diseases. This collaboration aims to leverage the expertise of both companies to…
-
Mabwell Bioscience’s 9MW3011 Earns US FDA Fast Track Designation for Polycythemia Vera Treatment
•
Mabwell (Shanghai) Bioscience Co., Ltd (SHA: 688062), a China-based biopharmaceutical company, has announced that it has received Fast Track Designation (FTD) from the US Food and Drug Administration (FDA) for its drug candidate 9MW3011 (MWTX-003/DISC-3405) for the treatment of patients with polycythemia vera (PV). This designation underscores the potential impact…
-
Sansure Biotech Secures CE Mark for 60 Molecular Diagnostic Products, Including Procalcitonin Assay Kit
•
Sansure Biotech Inc., a leading molecular diagnostics specialist based in China (SHA: 688289), has announced that it has received CE marks for 60 of its products, including a procalcitonin assay kit that utilizes chemiluminescent immunoassay technology. This significant milestone underscores the company’s commitment to expanding its global footprint and enhancing…
-
Abbott Expands Biosimilars Portfolio with mAbxience In-License Agreement
•
Abbott (NYSE: ABT) has announced the in-licensing of several biosimilar drugs from Spain-based biotechnology firm mAbxience for select markets in Latin America, Southeast Asia, the Middle East, and Africa. mAbxience, which had its majority stake acquired by German group Fresenius (ETR: FRE) from Argentina-based Insud Pharma last year, specializes in…
ADC / XDC AstraZeneca Auto-immune AZ Biotech BMS Bristol-Myers Squibb Cancer CAR-T Cell-therapy Clinical trial approval / initiation Clinical trial results Combination therapy CRO / CMO / CDMO CVD Diabetes Eli Lilly Finance Finanical Reports Gene therapy Hengrui Medicine J&J Johnson & Johnson Market approval filings Merck MSD Multi-specific antibodies NASDAQ: AZN NMPA Novartis NYSE: BMY NYSE: JNJ NYSE: LLY NYSE: MRK NYSE: NVS Obesity Ophthalmology PD-1/L1 Pfizer Potential first-in-class Product approvals Rare / orphan disease drugs SHA: 600276 TKIs (EGFR VEGF BTK etc.) Vaccine
